Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

IMPORTANCE: Nonclinical studies suggest that the combination of poly(ADP-ribose) polymerase and programmed cell death 1/programmed cell death–ligand 1 inhibitors has enhanced antitumor activity; however, the patient populations that may benefit from this combination have not been identified. OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Schram, Alison M., Colombo, Nicoletta, Arrowsmith, Edward, Narayan, Vivek, Yonemori, Kan, Scambia, Giovanni, Zelnak, Amelia, Bauer, Todd M., Jin, Ning, Ulahannan, Susanna V., Colleoni, Marco, Aftimos, Philippe, Donoghue, Mark T. A., Rosen, Ezra, Rudneva, Vasilisa A., Telli, Melinda L., Domchek, Susan M., Galsky, Matthew D., Hoyle, Margaret, Chappey, Colombe, Stewart, Ross, Blake-Haskins, John A., Yap, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673021/
https://www.ncbi.nlm.nih.gov/pubmed/36394867
http://dx.doi.org/10.1001/jamaoncol.2022.5218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673021/
https://www.ncbi.nlm.nih.gov/pubmed/36394867
http://dx.doi.org/10.1001/jamaoncol.2022.5218

Ejemplares similares